HUGEL, INC. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1,99,000 KRW | -1.24% |
|
+0.15% | +33.20% |
| 27/03 | Hugel, Inc. announces an Equity Buyback for KRW 50,000 million worth of its shares. | CI |
| 27/03 | Hugel, Inc. authorizes a Buyback Plan. | CI |
ETFs positioned on Hugel, Inc.
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.39% | 2 M€ | -14.14% | ||
| 0.01% | 4 M€ | -4.41% | - | |
| 0.00% | 112 M€ | +5.68% | - | |
| 0.00% | 34 M€ | +4.06% | - |
Hugel Inc is a Korea-based company mainly engaged in the manufacture of biopharmaceuticals. The Company's product portfolio consists of botulinum toxins which used for treatment of benign essential blepharospasm and temporary improvement of moderate to severe glabellar lines including 50 unit types, 100 unit types and 200unit types; hyaluronic acid (HA) fillers which used for temporary removal of facial wrinkles including the chaeum premium No.1, the chaeum premium No.2, the chaeum premium No.3m the chaeum premium No.4, the chaeum MID 20A, the chaeum DEEP 20A, the chaeum SUB-Q 20A and the chaeum VOLUS 20A; wellages, blue roses and other cosmetics. The Company sells its products in domestic and overseas markets.
Sector
Pharmaceuticals
Calendar
16/05/2024
- Non Deal Roadshow
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
1,99,000
KRW
Average target price
2,24,889
KRW
Spread / Average Target
+13.01%
EPS Revisions
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +33.20% | 159.17Cr | |
| -1.26% | 8.95TCr | |
| +2.76% | 4.07TCr | |
| -9.06% | 3.3TCr | |
| +55.32% | 2.47TCr | |
| -16.61% | 1.51TCr | |
| -9.14% | 1.28TCr | |
| -12.11% | 1.18TCr | |
| -43.61% | 1.16TCr | |
| +7.79% | 890.22Cr |
- Stock Market
- Equities
- A145020 Stock
- Funds and ETFs Hugel, Inc.